

David R Andes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6189406/publications.pdf>

Version: 2024-02-01

222
papers

26,088
citations

10956

71
h-index

6630

156
g-index

241
all docs

241
docs citations

241
times ranked

18474
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guidelines for the Management of Invasive Candidiasis: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009, 48, 503-535.	2.9	2,644
2	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, e1-e50.	2.9	2,489
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
4	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <i>Clinical Infectious Diseases</i> , 2010, 50, 1101-1111.	2.9	1,281
5	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 62, 409-417.	2.9	1,258
6	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , 2010, 50, 1091-1100.	2.9	1,194
7	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2012, 54, 1110-1122.	2.9	649
8	A Recently Evolved Transcriptional Network Controls Biofilm Development in <i>Candida albicans</i> . <i>Cell</i> , 2012, 148, 126-138.	13.5	607
9	Critical Role of Bcr1-Dependent Adhesins in <i>C. albicans</i> Biofilm Formation In Vitro and In Vivo. <i>PLoS Pathogens</i> , 2006, 2, e63.	2.1	443
10	Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 24-34.	1.4	442
11	Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. <i>Pediatric Infectious Disease Journal</i> , 1996, 15, 255-259.	1.1	425
12	Putative Role of β -1,3 Glucans in <i>Candida albicans</i> Biofilm Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 510-520.	1.4	362
13	In Vivo Pharmacodynamic Activity of Daptomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 63-68.	1.4	342
14	Epidemiology and Outcomes of Invasive Candidiasis Due to Non- <i>albicans</i> Species of <i>Candida</i> in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004-2008. <i>PLoS ONE</i> , 2014, 9, e101510.	1.1	338
15	Mechanisms of <i>Candida</i> biofilm drug resistance. <i>Future Microbiology</i> , 2013, 8, 1325-1337.	1.0	317
16	Complementary Adhesin Function in <i>C. albicans</i> Biofilm Formation. <i>Current Biology</i> , 2008, 18, 1017-1024.	1.8	293
17	Biofilm Matrix Regulation by <i>Candida albicans</i> Zap1. <i>PLoS Biology</i> , 2009, 7, e1000133.	2.6	286
18	Factors Associated with Mortality in Transplant Patients with Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2010, 50, 1559-1567.	2.9	269

#	ARTICLE	IF	CITATIONS
19	Antifungal Agents. Infectious Disease Clinics of North America, 2016, 30, 51-83.	1.9	264
20	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . Drug Resistance Updates, 2015, 21-22, 30-40.	6.5	262
21	Pharmacology of Systemic Antifungal Agents. Clinical Infectious Diseases, 2006, 43, S28-S39.	2.9	253
22	A <i>Candida</i> Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance. PLoS Pathogens, 2012, 8, e1002848.	2.1	240
23	Novel Entries in a Fungal Biofilm Matrix Encyclopedia. MBio, 2014, 5, e01333-14.	1.8	234
24	Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens, 2011, 7, e1002257.	2.1	231
25	The antimicrobial potential of <i>Streptomyces</i> from insect microbiomes. Nature Communications, 2019, 10, 516.	5.8	222
26	Genetic Basis of <i>Candida</i> Biofilm Resistance Due to Drug-Induced Sequestering Matrix Glucan. Journal of Infectious Diseases, 2010, 202, 171-175.	1.9	220
27	Protein Binding: Do We Ever Learn?. Antimicrobial Agents and Chemotherapy, 2011, 55, 3067-3074.	1.4	212
28	Synergistic Effect of Calcineurin Inhibitors and Fluconazole against <i>Candida albicans</i> Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 1127-1132.	1.4	205
29	Commensal Protection of <i>Staphylococcus aureus</i> against Antimicrobials by <i>Candida albicans</i> Biofilm Matrix. MBio, 2016, 7, .	1.8	202
30	Fungal Biofilms, Drug Resistance, and Recurrent Infection. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a019729-a019729.	2.9	196
31	<i>Candida albicans</i> biofilm development, modeling a host-pathogen interaction. Current Opinion in Microbiology, 2006, 9, 340-345.	2.3	190
32	Role of Fks1p and Matrix Glucan in <i>Candida albicans</i> Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene. Antimicrobial Agents and Chemotherapy, 2010, 54, 3505-3508.	1.4	188
33	<i>Candida albicans</i> biofilm-induced vesicles confer drug resistance through matrix biogenesis. PLoS Biology, 2018, 16, e2006872.	2.6	173
34	Time Course Global Gene Expression Analysis of an In Vivo <i>Candida</i> Biofilm. Journal of Infectious Diseases, 2009, 200, 307-313.	1.9	156
35	In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrobial Agents and Chemotherapy, 2003, 47, 1179-1186.	1.4	154
36	Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2008, 52, 3022-3028.	1.4	142

#	ARTICLE	IF	CITATIONS
37	An expanded regulatory network temporally controls <i>Candida albicans</i> biofilm formation. <i>Molecular Microbiology</i> , 2015, 96, 1226-1239.	1.2	140
38	Interface of <i>Candida albicans</i> Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation. <i>Eukaryotic Cell</i> , 2011, 10, 1660-1669.	3.4	139
39	Community participation in biofilm matrix assembly and function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4092-4097.	3.3	139
40	Development and Validation of an <i>In Vivo Candida albicans</i> Biofilm Denture Model. <i>Infection and Immunity</i> , 2010, 78, 3650-3659.	1.0	138
41	Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 167-172.	1.0	136
42	The epidemiology and outcomes of invasive <i>Candida</i> infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <i>Transplant Infectious Disease</i> , 2016, 18, 921-931.	0.7	135
43	Voriconazole Use for Endemic Fungal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1648-1651.	1.4	130
44	Optimizing a <i>Candida</i> Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1426-1433.	1.8	127
45	Histoplasmosis Complicating Tumor Necrosis Factor- α Blocker Therapy: A Retrospective Analysis of 98 Cases. <i>Clinical Infectious Diseases</i> , 2015, 61, 409-417.	2.9	111
46	Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm. <i>ISME Journal</i> , 2018, 12, 1427-1442.	4.4	111
47	Comparative Phenotypic Analysis of the Major Fungal Pathogens <i>Candida parapsilosis</i> and <i>Candida albicans</i> . <i>PLoS Pathogens</i> , 2014, 10, e1004365.	2.1	108
48	<i>Candida</i> -streptococcal interactions in biofilm-associated oral diseases. <i>PLoS Pathogens</i> , 2018, 14, e1007342.	2.1	103
49	<i>In Vivo</i> Pharmacodynamic Activity of the Glycopeptide Dalbavancin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1633-1642.	1.4	102
50	Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2113-2121.	1.4	102
51	A marine microbiome antifungal targets urgent-threat drug-resistant fungi. <i>Science</i> , 2020, 370, 974-978.	6.0	102
52	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e364-e374.	4.6	99
53	Forazoline: A Marine-Derived Polyketide with Antifungal <i>In Vivo</i> Efficacy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 11583-11586.	7.2	98
54	Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in <i>Candida dubliniensis</i> . <i>Eukaryotic Cell</i> , 2011, 10, 803-819.	3.4	97

#	ARTICLE	IF	CITATIONS
55	Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	94
56	Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. <i>PLoS Pathogens</i> , 2016, 12, e1005828.	2.1	93
57	Pharmacokinetics and Pharmacodynamics of Antifungals. <i>Infectious Disease Clinics of North America</i> , 2006, 20, 679-697.	1.9	92
58	CNS pharmacokinetics of antifungal agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 573-581.	1.5	92
59	Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2156-2162.	1.4	91
60	β -1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 1705-1712.	1.9	85
61	Antifungal Pharmacokinetics and Pharmacodynamics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a019653-a019653.	2.9	85
62	Optimizing antifungal choice and administration. <i>Current Medical Research and Opinion</i> , 2013, 29, 13-18.	0.9	83
63	Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an <i>In Vivo</i> Murine Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1265-1272.	1.4	83
64	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. <i>Journal of Infectious Diseases</i> , 2020, 222, S175-S198.	1.9	83
65	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018, 5, 300-326.	1.4	81
66	Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. <i>Clinics in Laboratory Medicine</i> , 2004, 24, 477-502.	0.7	79
67	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). <i>Medical Mycology</i> , 2015, 53, 440-446.	0.3	79
68	Dual action antifungal small molecule modulates multidrug efflux and TOR signaling. <i>Nature Chemical Biology</i> , 2016, 12, 867-875.	3.9	79
69	Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 6390-6400.	1.4	79
70	Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an <i>In Vivo</i> Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and <i>cyp51</i> Mutant Isolates of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6284-6289.	1.4	78
71	Regulatory Role of Glycerol in <i>Candida albicans</i> Biofilm Formation. <i>MBio</i> , 2013, 4, e00637-12.	1.8	77
72	Conserved and Divergent Roles of Bcr1 and CFEM Proteins in <i>Candida parapsilosis</i> and <i>Candida albicans</i> . <i>PLoS ONE</i> , 2011, 6, e28151.	1.1	76

#	ARTICLE	IF	CITATIONS
73	A Dual-Responsive Antibiotic-Loaded Nanoparticle Specifically Binds Pathogens and Overcomes Antimicrobial-Resistant Infections. <i>Advanced Materials</i> , 2021, 33, e2006772.	11.1	76
74	Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	75
75	Nontoxic antimicrobials that evade drug resistance. <i>Nature Chemical Biology</i> , 2015, 11, 481-487.	3.9	74
76	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	71
77	A Histone Deacetylase Complex Mediates Biofilm Dispersal and Drug Resistance in <i>Candida albicans</i> . <i>MBio</i> , 2014, 5, e01201-14.	1.8	70
78	Comparative analysis of <i>Candida</i> biofilm quantitation assays. <i>Medical Mycology</i> , 2012, 50, 214-218.	0.3	69
79	Posaconazole Pharmacodynamic Target Determination against Wild-Type and <i>Cyp51</i> Mutant Isolates of <i>Aspergillus fumigatus</i> in an <i>In Vivo</i> Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 579-585.	1.4	68
80	Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2473-2478.	1.4	66
81	Pharmacodynamic Optimization for Treatment of Invasive <i>Candida auris</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	65
82	Global Identification of Biofilm-Specific Proteolysis in <i>Candida albicans</i> . <i>MBio</i> , 2016, 7, .	1.8	63
83	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in <i>Aspergillus fumigatus</i> . <i>PeerJ</i> , 2013, 1, e4.	0.9	63
84	Reduced Biocide Susceptibility in <i>Candida albicans</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3411-3413.	1.4	61
85	Host Contributions to Construction of Three Device-Associated <i>Candida albicans</i> Biofilms. <i>Infection and Immunity</i> , 2015, 83, 4630-4638.	1.0	58
86	Contributions of the Biofilm Matrix to <i>Candida</i> Pathogenesis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 21.	1.5	58
87	<i>Candida albicans</i> FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006763.	2.1	57
88	Pharmacodynamics of Fluoroquinolones in Experimental Models of Endocarditis. <i>Clinical Infectious Diseases</i> , 1998, 27, 47-50.	2.9	56
89	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against <i>Candida</i> spp. in a Neutropenic Disseminated Candidiasis Mouse Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	56
90	Pharmacodynamic Evaluation of Rezafungin (CD101) against <i>Candida auris</i> in the Neutropenic Mouse Invasive Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	56

#	ARTICLE	IF	CITATIONS
91	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3056-3062.	1.3	54
92	Transcriptional rewiring over evolutionary timescales changes quantitative and qualitative properties of gene expression. <i>ELife</i> , 2016, 5, .	2.8	54
93	Isavuconazole Pharmacodynamic Target Determination for Candida Species in an <i>In Vivo</i> Murine Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5642-5648.	1.4	52
94	The Extracellular Matrix of Fungal Biofilms. <i>Advances in Experimental Medicine and Biology</i> , 2016, 931, 21-35.	0.8	52
95	Conservation and Divergence in the <i>Candida</i> Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. <i>MBio</i> , 2018, 9, .	1.8	52
96	Comparison of In Vitro Susceptibility Characteristics of <i>Candida</i> Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2404-2410.	1.8	51
97	A small molecule produced by <i>Lactobacillus</i> species blocks <i>Candida albicans</i> filamentation by inhibiting a DYRK1-family kinase. <i>Nature Communications</i> , 2021, 12, 6151.	5.8	50
98	Comparative Pharmacodynamics of the New Oxazolidinone Tedizolid Phosphate and Linezolid in a Neutropenic Murine <i>Staphylococcus aureus</i> Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5916-5922.	1.4	49
99	Fungal Biofilms: <i>In Vivo</i> Models for Discovery of Anti-Biofilm Drugs. <i>Microbiology Spectrum</i> , 2015, 3, .	1.2	49
100	An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen <i>Candida auris</i> . <i>Nature Communications</i> , 2020, 11, 6429.	5.8	49
101	Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting. <i>Critical Care Clinics</i> , 2011, 27, 123-147.	1.0	48
102	Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> at Inocula of 10 ⁵ and 10 ⁷ CFU Injected into Opposite Thighs of Neutropenic Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1434-1441.	1.4	48
103	Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 761-767.	1.3	48
104	Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	48
105	Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3398-3406.	1.4	45
106	<i>In Vivo</i> Pharmacodynamic Target Assessment of Delafloxacin against <i>Staphylococcus aureus</i> , <i>Streptococcus pneumoniae</i> , and <i>Klebsiella pneumoniae</i> in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4764-4769.	1.4	44
107	The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: Highly selective cytotoxic agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 208-219.	2.6	43
108	In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. <i>Current Opinion in Pharmacology</i> , 2017, 36, 94-99.	1.7	42

#	ARTICLE	IF	CITATIONS
109	Coordination of fungal biofilm development by extracellular vesicle cargo. <i>Nature Communications</i> , 2021, 12, 6235.	5.8	42
110	Clinical utility of antifungal pharmacokinetics and pharmacodynamics. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 533-540.	1.3	41
111	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	2.3	41
112	Bypass of <i>Candida albicans</i> Filamentation/Biofilm Regulators through Diminished Expression of Protein Kinase Cak1. <i>PLoS Genetics</i> , 2016, 12, e1006487.	1.5	39
113	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via <i>In Vivo</i> Pharmacodynamic Evaluation against <i>Candida glabrata</i> with and without <i>FKS</i> Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5875-5882.	1.4	38
114	Rat Indwelling Urinary Catheter Model of <i>Candida albicans</i> Biofilm Infection. <i>Infection and Immunity</i> , 2014, 82, 4931-4940.	1.0	38
115	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against <i>Streptococcus pneumoniae</i> in the Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	37
116	We can do better: a fresh look at echinocandin dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i44-i50.	1.3	37
117	APX001 Pharmacokinetic/Pharmacodynamic Target Determination against <i>Aspergillus fumigatus</i> in an <i>In Vivo</i> Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	37
118	Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity. <i>Nanomedicine</i> , 2018, 13, 1139-1155.	1.7	36
119	<i>In Vivo</i> Pharmacodynamic Target Assessment of Eravacycline against <i>Escherichia coli</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	35
120	Biomaterial armor in leaf-cutter ants. <i>Nature Communications</i> , 2020, 11, 5792.	5.8	34
121	<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1258-1264.	1.4	32
122	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019, 68, 850-853.	2.9	31
123	Novel approaches for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> : Using nanoparticles to overcome multidrug resistance. <i>Drug Discovery Today</i> , 2021, 26, 31-43.	3.2	30
124	Impact of <i>In Vivo</i> Triazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy against <i>Cyp51</i> Mutant Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5438-5447.	1.4	29
125	Searching for new derivatives of neocryptolepine: Synthesis, antiproliferative, antimicrobial and antifungal activities. <i>European Journal of Medicinal Chemistry</i> , 2014, 78, 304-313.	2.6	29
126	Intraluminal Release of an Antifungal β -Peptide Enhances the Antifungal and Anti-Biofilm Activities of Multilayer-Coated Catheters in a Rat Model of Venous Catheter Infection. <i>ACS Biomaterials Science and Engineering</i> , 2016, 2, 112-121.	2.6	29

#	ARTICLE	IF	CITATIONS
127	Turbinmicin inhibits <i>Candida</i> biofilm growth by disrupting fungal vesicle-mediated trafficking. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	29
128	Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5714-5716.	1.4	28
129	Pleiotropic effects of the vacuolar ABC transporter MLT1 of <i>Candida albicans</i> on cell function and virulence. <i>Biochemical Journal</i> , 2016, 473, 1537-1552.	1.7	28
130	Clinical pharmacodynamics of antifungals. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 635-649.	1.9	27
131	Pyonitrins Aâ€“D: Chimeric Natural Products Produced by <i>Pseudomonas protegens</i> . <i>Journal of the American Chemical Society</i> , 2019, 141, 17098-17101.	6.6	27
132	Large-scale production and isolation of <i>Candida</i> biofilm extracellular matrix. <i>Nature Protocols</i> , 2016, 11, 2320-2327.	5.5	26
133	Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	26
134	<i>In Vivo</i> Pharmacodynamics of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	26
135	Evolution of the complex transcription network controlling biofilm formation in <i>Candida</i> species. <i>ELife</i> , 2021, 10, .	2.8	25
136	Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	24
137	Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis. <i>ACS Central Science</i> , 2021, 7, 292-299.	5.3	23
138	Antifungal PK/PD Considerations in Fungal Pulmonary Infections. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 783-794.	0.8	22
139	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	22
140	The <i>Candida albicans</i> biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation. <i>PLoS Biology</i> , 2019, 17, e3000422.	2.6	22
141	Use of an Animal Model of Disseminated Candidiasis in the Evaluation of Antifungal Therapy. , 2005, 118, 111-128.		21
142	Targeting fungal membrane homeostasis with imidazopyrazoindoles impairs azole resistance and biofilm formation. <i>Nature Communications</i> , 2022, 13, .	5.8	21
143	<i>In vivo</i> pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iii5-iii10.	1.3	20
144	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	20

#	ARTICLE	IF	CITATIONS
145	Application of 3D NMR for Structure Determination of Peptide Natural Products. <i>Journal of Organic Chemistry</i> , 2015, 80, 8713-8719.	1.7	19
146	Targeting Fibronectin To Disrupt In Vivo <i>Candida albicans</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3152-3155.	1.4	18
147	The protein kinase Ire1 impacts pathogenicity of <i>Candida albicans</i> by regulating homeostatic adaptation to endoplasmic reticulum stress. <i>Cellular Microbiology</i> , 2021, 23, e13307.	1.1	18
148	Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. <i>Drug Resistance Updates</i> , 2004, 7, 185-194.	6.5	17
149	Modeling of Fungal Biofilms Using a Rat Central Vein Catheter. <i>Methods in Molecular Biology</i> , 2012, 845, 547-556.	0.4	17
150	Insights into fungal pathogenesis from the iatrogenic epidemic of <i>Exserohilum rostratum</i> fungal meningitis. <i>Fungal Genetics and Biology</i> , 2013, 61, 143-145.	0.9	17
151	WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo- β -Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	17
152	Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in <i>Candida albicans</i> . <i>Cellular Microbiology</i> , 2017, 19, e12767.	1.1	16
153	Impact of Triazole Therapeutic Drug Monitoring Availability and Timing. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
154	Determination of Pharmacodynamic Target Exposures for Rezafungin against <i>Candida tropicalis</i> and <i>Candida dubliniensis</i> in the Neutropenic Mouse Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
155	Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 399-445.	1.9	16
156	Chemical Exchanges between Multilateral Symbionts. <i>Organic Letters</i> , 2021, 23, 1648-1652.	2.4	16
157	Pharmacokinetics and Pharmacodynamics of Tetracyclines. <i>Infectious Disease and Therapy</i> , 2007, , 267-278.	0.0	16
158	Preventing <i>Pseudomonas aeruginosa</i> Biofilms on Indwelling Catheters by Surface-Bound Enzymes. <i>ACS Applied Bio Materials</i> , 2021, 4, 8248-8258.	2.3	16
159	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. <i>Journal of Biological Chemistry</i> , 2019, 294, 2700-5412.	1.6	15
160	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	15
161	The Role of In Vitro Susceptibility Testing in the Management of <i>Candida</i> and <i>Aspergillus</i> . <i>Journal of Infectious Diseases</i> , 2017, 216, S452-S457.	1.9	14
162	<i>In Vivo</i> Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6568-6574.	1.4	13

#	ARTICLE	IF	CITATIONS
163	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3023-3028.	1.3	13
164	Editorial Commentary: Antifungal Therapeutic Drug Monitoring Progress: Getting It Right the First Time. <i>Clinical Infectious Diseases</i> , 2012, 55, 391-393.	2.9	12
165	Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation. <i>Pharmaceutical Research</i> , 2017, 34, 1115-1124.	1.7	12
166	A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation. <i>Transplant Infectious Disease</i> , 2019, 21, e13156.	0.7	11
167	<i>In Vivo</i> Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
168	<i>In Vivo</i> Pharmacodynamic Target Determination for Delafloxacin against <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	9
169	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmaceutics</i> , 2021, 13, 1791.	2.0	9
170	Continuous flow synthesis and antimicrobial evaluation of NHC* silver carboxylate derivatives of SBC3 <i>in vitro</i> and <i>in vivo</i> . <i>Metallomics</i> , 2021, 13, .	1.0	9
171	Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 991-8.	2.3	9
172	Pharmacokinetics—pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 371-382.	0.8	8
173	<i>In Vivo</i> Pharmacodynamic Evaluation of Omadacycline against <i>Staphylococcus aureus</i> in the Neutropenic Mouse Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
174	Old <i>In Vitro</i> Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa084.	0.4	8
175	The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses. <i>Current Infectious Disease Reports</i> , 2010, 12, 471-478.	1.3	7
176	Identification of the <i>In Vivo</i> Pharmacokinetics and Pharmacodynamic Driver of Iclaprim. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	7
177	Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical $\hat{1}^2$ -Peptides To Prevent <i>Candida albicans</i> Biofilm Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	7
178	Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 288-296.	1.3	7
179	Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived <i>Pseudonocardia</i> sp. Bacterium. <i>Organic Letters</i> , 2022, 24, 3998-4002.	2.4	7
180	Development of New Strategies for Echinocandins: Progress in Translational Research. <i>Clinical Infectious Diseases</i> , 2015, 61, S601-S603.	2.9	6

#	ARTICLE	IF	CITATIONS
181	The Role of New Posaconazole Formulations in the Treatment of <i>Candida albicans</i> Infections: Data from an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6
182	Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 2411-2426.	1.7	5
183	Review of techniques for diagnosis of catheter-related <i>Candida</i> biofilm infections. <i>Current Fungal Infection Reports</i> , 2008, 2, 237-243.	0.9	4
184	<i>Candida</i> Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms. , 2017, , 77-92.		4
185	Characterization of an <i>Uncinocarpus reesii</i> -expressed recombinant tube precipitin antigen of <i>Coccidioides posadasii</i> for serodiagnosis. <i>PLoS ONE</i> , 2019, 14, e0221228.	1.1	4
186	Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against <i>Streptococcus pneumoniae</i> Using Data from a Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	4
187	Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?. <i>Clinical Infectious Diseases</i> , 2019, 68, 1990-1992.	2.9	4
188	Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <i>Candida albicans</i> Using a Validated <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
189	Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2256-2264.	0.5	4
190	Preparation of <i>Candida albicans</i> Biofilms for Transmission Electron Microscopy. <i>Bio-protocol</i> , 2013, 3, .	0.2	4
191	A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against <i>Candida albicans</i> Biofilms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 108.	1.8	4
192	Antifungal Pharmacokinetics and Pharmacodynamics. , 2011, , 121-134.		3
193	Fungal Biofilms: <i>In Vivo</i> Models for Discovery of Anti-Biofilm Drugs. , 2015, , 33-49.		3
194	Traditional PK-PD Indices for Efficacy – Can We Do Better?. <i>Open Forum Infectious Diseases</i> , 2017, 4, S298-S298.	0.4	3
195	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3
196	Preparation of <i>Candida albicans</i> Biofilms Using an <i>in vivo</i> Rat Central Venous Catheter Model. <i>Bio-protocol</i> , 2013, 3, .	0.2	3
197	Animal Models to Evaluate Anti-infective Pharmacodynamics. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 59-87.	0.1	2
198	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2017, , 369-384.		2

#	ARTICLE	IF	CITATIONS
199	Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	2
200	Contributions of Extracellular Vesicles to Fungal Biofilm Pathogenesis. <i>Current Topics in Microbiology and Immunology</i> , 2021, 432, 67-79.	0.7	2
201	Race and invasive fungal infection in solid organ transplant recipients. <i>Ethnicity and Disease</i> , 2014, 24, 382-5.	1.0	2
202	Polymeric Micelles for the Delivery of Polyene Antibiotics. <i>ACS Symposium Series</i> , 2006, , 14-26.	0.5	1
203	Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy. <i>Current Fungal Infection Reports</i> , 2008, 2, 12-19.	0.9	1
204	Antifungal therapy: current concepts and evidence-based management. <i>Current Medical Research and Opinion</i> , 2013, 29, 289-290.	0.9	1
205	Reply to Oude Lashof and Vogelaers. <i>Clinical Infectious Diseases</i> , 2013, 56, 1515-1516.	2.9	1
206	Pharmacodynamics of Quinolone Antimicrobial Agents. , 2014, , 147-155.		1
207	Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
208	Pharmacodynamic Optimization for the Treatment of Invasive <i>Candida auris</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, S73-S73.	0.4	1
209	1389. Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model Against <i>S. aureus</i> (SA) and <i>S. pneumoniae</i> (SPN). <i>Open Forum Infectious Diseases</i> , 2018, 5, S426-S426.	0.4	1
210	Candidemia in the Growing Opioid Epidemic: A Distinct and Emerging Entity. <i>Clinical Infectious Diseases</i> , 2020, 71, 1738-1740.	2.9	1
211	Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo-Lactamase-1. <i>Marine Drugs</i> , 2020, 18, 295.	2.2	1
212	Azoles. , 2011, , 61-93.		1
213	Imaging of the Development and Therapeutic Response of an In Vivo Fungal Catheter Biofilm. <i>Microscopy Today</i> , 2005, 13, 30-33.	0.2	0
214	The Microbe-Host Interface in Respiratory Tract Infections Edited by Jan L. L. Kimpen and Octavio Ramilo Wymondham, UK: Horizon Bioscience, 2005. 323 pp., illustrated. \$139.95 (cloth). <i>Clinical Infectious Diseases</i> , 2005, 41, 767-768.	2.9	0
215	Comparative In Vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against <i>Staphylococcus aureus</i> . <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
216	Antifungal Pharmacokinetics and Pharmacodynamics. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 369-383.	0.1	0

#	ARTICLE	IF	CITATIONS
217	In Vivo Candida Device Biofilm Models. , 2017, , 93-113.		0
218	Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species. Open Forum Infectious Diseases, 2017, 4, S298-S298.	0.4	0
219	Echinocandins. , 2021, , 438-448.		0
220	Treatment of Community-Acquired Respiratory Tract Infections with Other Antibiotics. , 2003, , 145-153.		0
221	Antifungal Agents Pharmacokinetics and Pharmacodynamics of Amphotericin B. Infectious Disease and Therapy, 2007, , 315-326.	0.0	0
222	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2014, , 1-14.		0